Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Animesh D. Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2023-185185

Published: 2023

Journal Articles

Type 1/like Calr Mutation in Momelotinib-Treated Patients with Myelofibrosis Is the Most Prominent Predictor of Drug Survival and Longevity without Transplant

Ayalew Tefferi, Animesh D. Pardanani, Kebede Begna, Aref Al-Kali, William J. Hogan, Mark R. Litzow, Naseema Gangat

Blood (2023) 142 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2023-178869

Published: 2023

Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood (2023) 142 (Supplement 1): 591.

https://doi.org/10.1182/blood-2023-178837

Published: 2023

Journal Articles

Patient Outcomes after Initial High Dose Versus Low Dose Romiplostim for Inpatient Management of Immune Thrombocytopenia

Elizabeth King, Uzo Abajue, Amanda Pawlenty, Huong Lan Truong, Sabrina Fischer, Alexandra P. Wolanskyj-Spinner, Rajiv K. Pruthi, Carl C. Hook, Animesh D. Pardanani, Aneel Ashrani, Ewa Wysokinska, Surbhi Shah, Ronald S. Go

Blood (2023) 142 (Supplement 1): 393.

https://doi.org/10.1182/blood-2023-180279

Published: 2023

Journal Articles

ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis

Maymona Abdelmagid, Jeanne Palmer, James M. Foran, Aref Al-Kali, Omer Karrar, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2023-180235

Published: 2023

Journal Articles

C3+ and C3- Warm Autoimmune Hemolytic Anemias: A Comparison of Clinical Characteristics and Treatment Outcomes

Jordan Nunnelee, Jithma Prasad Abeykoon, Aneel Ashrani, Michelle Ann Elliott, Carl C. Hook, Animesh D. Pardanani, Rajiv K. Pruthi, Rachelle Rouse, Meera Sridharan, Alexandra P. Wolanskyj-Spinner, Ronald S. Go

Blood (2023) 142 (Supplement 1): 5195.

https://doi.org/10.1182/blood-2023-174805

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

Kristen McCullough, Omer Karrar, Moazah Iftikhar, Maymona Abdelmagid, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Mrinal M. Patnaik, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 5925.

https://doi.org/10.1182/blood-2023-182326

Published: 2023

Journal Articles

A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count

Ayalew Tefferi, Giuseppe Gaetano Loscocco, Faiqa Farrukh, Natasha Szuber, Francesco Mannelli, Animesh D. Pardanani, Curtis A. Hanson, Valerio De Stefano, Tiziano Barbui, Paola Guglielmelli, Naseema Gangat, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 238.

https://doi.org/10.1182/blood-2021-149140

Published: 2021

Journal Articles

Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90

Kebede H. Begna, Naseema Gangat, Mithun V. Shah, Hassan B. Alkhateeb, Mrinal M. Patnaik, Aref Al-Kali, Michelle A. Elliot, William J Hogan, Mark R. Litzow, C. Christopher Hook, Abhishek A. Mangaonkar, David S Viswanatha, Dong Chen, Animesh D. Pardanani, Rhett P. Ketterling, Ayalew Tefferi

Blood (2021) 138 (Supplement 1): 1267.

https://doi.org/10.1182/blood-2021-147485

Published: 2021

Journal Articles

Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms

Faiqa Farrukh, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Animesh D. Pardanani, Curtis A. Hanson, Valerio De Stefano, Tiziano Barbui, Naseema Gangat, Alessandro M. Vannucchi, Ayalew Tefferi

Blood (2021) 138 (Supplement 1): 3651.

https://doi.org/10.1182/blood-2021-149207

Published: 2021

Journal Articles

The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events

Naseema Gangat, Natasha Szuber, Yamna Jadoon, Faiqa Farrukh, Elena Rossi, Francesco Ramundo, Curtis A. Hanson, Alexandra P. Wolanskyj, Animesh D. Pardanani, Valerio De Stefano, Alessandro M. Vannucchi, Tiziano Barbui, Ayalew Tefferi

Blood (2021) 138 (Supplement 1): 3630.

https://doi.org/10.1182/blood-2021-149223

Published: 2021

Journal Articles

Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases

Ayalew Tefferi, Jaya Kittur, Faiqa Farrukh, Kebede H. Begna, Mrinal M. Patnaik, Aref Al-Kali, Michelle A Elliott, Kaaren K. Reichard, Naseema Gangat, Animesh D. Pardanani

Blood (2021) 138 (Supplement 1): 3657.

https://doi.org/10.1182/blood-2021-151009

Published: 2021

Journal Articles

The Anatomy of Recurrent Thrombosis and Its Risk Factors in Myeloproliferative Neoplasms

Silvia Betti, MD, Daniela Barraco, MD, Mythri Mudireddy, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 4190.

https://doi.org/10.1182/blood.V130.Suppl_1.4190.4190

Published: 2017

Journal Articles

Phenotypic and Prognostic Relevance of the Who Diagnostic Distinction between Polycythemia Vera and JAK2 -Mutated Essential Thrombocythemia: Combined Analysis of 785 Informative Cases

Silvia Betti, MD, Daniela Barraco, MD, Mythri Mudireddy, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 1645.

https://doi.org/10.1182/blood.V130.Suppl_1.1645.1645

Published: 2017

Journal Articles

Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series

Jennifer Yui, MD, Mythri Mudireddy, MBBS, Mrinal M Patnaik, MBBS, Naseema Gangat, MBBS, Aref Al-Kali, MD, Michelle Elliott, MD, William J. Hogan, MBChB, C. Christopher Hook, MD, Alexandra P Wolanskyj, MD, Mark R. Litzow, MD, Matthew T Howard, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Kebede H. Begna, MD

Blood (2016) 128 (22): 2798.

https://doi.org/10.1182/blood.V128.22.2798.2798

Published: 2016

Journal Articles

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

Ayalew Tefferi, Terra L. Lasho, Alexander Tischer, Emnet A. Wassie, Christy M. Finke, Alem A. Belachew, Rhett P. Ketterling, Curtis A. Hanson, Animesh D. Pardanani

Blood (2014) 124 (15): 2465–2466.

https://doi.org/10.1182/blood-2014-07-588426

Published: 2014

Includes: Supplemental data

Journal Articles

Telomere Length In Granulocyte, Mononuclear, CD34 and CD3 Cell Fractions In Primary Myelofibrosis and Age Matched Controls

Rebecca R Laborde, PhD, Terra L Lasho, MT, (ASCP), Steven A Zincke, Christy Finke, BS, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 4069.

https://doi.org/10.1182/blood.V122.21.4069.4069

Published: 2013

Journal Articles

Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies

Meera Sridharan, MD, PhD, Aref Al-Kali, MD, Aneel A. Ashrani, MBBS, MSc, Kebede Begna, MD, Michelle Elliott, William J. Hogan, MBChB, Carl C. Hook, MD, Scott H. Kaufmann, MD, PhD, Louis Letendre, MD, Mark R. Litzow, MD, Mrinal M. Patnaik, MBBS, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Alexandra Wolanskyj, MD, Rajiv K. Pruthi, MBBS

Blood (2013) 122 (21): 5000.

https://doi.org/10.1182/blood.V122.21.5000.5000

Published: 2013

Journal Articles

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

Animesh D. Pardanani, MBBS, PhD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Ramy A. Abdelrahman, MBBCh, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 2824.

https://doi.org/10.1182/blood.V122.21.2824.2824

Published: 2013

NARROW

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Type 1/like Calr Mutation in Momelotinib-Treated Patients with Myelofibrosis Is the Most Prominent Predictor of Drug Survival and Longevity without Transplant

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Patient Outcomes after Initial High Dose Versus Low Dose Romiplostim for Inpatient Management of Immune Thrombocytopenia

ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis

C3+ and C3- Warm Autoimmune Hemolytic Anemias: A Comparison of Clinical Characteristics and Treatment Outcomes

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count

Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90

Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms

The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events

Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases

The Anatomy of Recurrent Thrombosis and Its Risk Factors in Myeloproliferative Neoplasms

Phenotypic and Prognostic Relevance of the Who Diagnostic Distinction between Polycythemia Vera and JAK2 -Mutated Essential Thrombocythemia: Combined Analysis of 785 Informative Cases

Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

Telomere Length In Granulocyte, Mononuclear, CD34 and CD3 Cell Fractions In Primary Myelofibrosis and Age Matched Controls

Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only